Physician profile
Cliff A Gronseth
NPI 1811983802
$6,819.14
in general payments reported to CMS, 2019-2025
14 companies · $673 in 2025
The $673 reported for 2025 was more than what 83% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $5,500 · 2021: $87.85 · 2022: $117 · 2023: $132 · 2024: $310 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Konica Minolta Healthcare Americas, INC | $5,500.00 | 2020 | |
| Abbvie INC. | $383.25 | 2022-2025 | |
| Gemini Mountain Medical, LLC | $174.80 | 2025 | |
| Arthrex, INC. | $156.76 | 2025 | |
| Abbott Laboratories | $125.33 | 2021-2025 | Proclaim, Eterna |
| Pacira Pharmaceuticals Incorporated | $121.26 | 2023-2025 | Iovera, Zilretta |
| Boston Scientific Corporation | $98.69 | 2024-2025 | Wavewriter Alpha Prime 16, Na, General - Pain Management |
| Depuy Synthes Sales INC. | $81.96 | 2024-2025 | Monovisc, Orthovisc |
| Allergan, INC. | $51.94 | 2021-2022 | |
| Bioventus LLC | $39.89 | 2024-2025 | Durolane |
| Vertex Pharmaceuticals Incorporated | $25.82 | 2025 | |
| Averitas Pharma INC. | $24.95 | 2024 | Qutenza |
| Siemens Medical Solutions USA, INC. | $17.78 | 2022 | |
| Avanos Medical | $16.71 | 2024 | Genvisc 850 Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cliff Gronseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.